Search

Your search keyword '"Viglietti R"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Viglietti R" Remove constraint Author: "Viglietti R"
73 results on '"Viglietti R"'

Search Results

1. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

2. Differences among confirmed and not-confirmed COVID-19 patients at 'D.Cotugno' hospital, Naples (Italy): what we learned from first suspected cases?

3. COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study

5. Incidence of Malignancies in HIV‐Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study

6. Epi-aortic lesions, pathologic FMD, endothelial activation and inflammatory markers in advanced naïve HIV-infected patients starting ART therapy

7. Modificazioni dell'intima-media carotidea, attivazione endoteliale e marker di infiammazione in pazienti HIV-positivi naive avanzati che iniziano terapia antiretrovirale: studio PREVALEAT II. Rapporto in itinere

8. Ultrasonographic carotid intima media changes, endothelial activation and inflammatory markers in HIV+ patients starting HAART: a perspective study. PREVALEAT II

9. Carotid intima media thickness changes, endothelial activation and inflammatory markers in advanced naïve HIV patients starting antiretroviral therapy

10. Modificazioni dell'intima-media carotidea, attivazione endoteliale e marker di infiammazione in pazienti HIV-positivi naive avanzati che iniziano terapia antiretrovirale: studio PREVALEAT II. Rapporto preliminare

11. Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs

12. Carotid intima media thickness changes, endothelial activation and inflammatory markers in advanced naive HIV infected patients starting antiretroviral therapy: PREVALEAT II Study. A preliminary report

13. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008

14. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

15. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts

16. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

17. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

18. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

19. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study

20. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

21. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

22. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures

23. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

24. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients

25. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

26. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

27. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

28. Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy

29. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

30. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

31. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

32. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

33. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

34. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study

35. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads

36. Economic evaluation of HIV treatments: The I.CO.N.A. cohort study

37. Carotid intima media thickness changes, endothelial activation and inflammatory markers in advanced naïve HIV patients starting antiretroviral therapy

39. Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

40. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

42. Comparative transcriptional profiling in HIV-infected patients using human stress arrays: clues to metabolic syndrome

43. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

44. Use of lung ultrasound in covid-19: Comparison with ultra-high-resolution computed tomography among 29 patients at 'd. cotugno' hospital, Naples, Italy

45. COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study

46. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts

47. Role of FAP48 in HIV-associated lipodystrophy

48. Role of NEDD8 in HIV-associated lipodystrophy

49. Does COVID-19 Vaccination with BNT162b2 Influence HIV-Related Immunological and Virological Markers? Data from 235 Persons Living with HIV at Cotugno Hospital, Naples, Italy: Immune Response After Second and Third Doses, and Influence on Immunovirological Markers.

50. Unexpected effects of COVID-19 outbreak: adaption of Anti-Retroviral Therapy (ART) delivery policies improved adherence in a population of People Living With HIV (PLWH).

Catalog

Books, media, physical & digital resources